These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32296414)

  • 41. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
    Savoldo B; Rooney CM; Di Stasi A; Abken H; Hombach A; Foster AE; Zhang L; Heslop HE; Brenner MK; Dotti G
    Blood; 2007 Oct; 110(7):2620-30. PubMed ID: 17507664
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
    Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
    Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Soluble CD30: a possible serum tumor marker for primary effusion lymphoma.
    Michai M; Goto H; Hattori S; Vaeteewoottacharn K; Wongkham C; Wongkham S; Okada S
    Asian Pac J Cancer Prev; 2012; 13(10):4939-41. PubMed ID: 23244086
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD30 is involved in inhibition of T-cell proliferation by Hodgkin's Reed-Sternberg cells.
    Su CC; Chiu HH; Chang CC; Chen JC; Hsu SM
    Cancer Res; 2004 Mar; 64(6):2148-52. PubMed ID: 15026356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of MDR1 Overcomes Resistance to Brentuximab Vedotin in Hodgkin Lymphoma.
    Chen R; Herrera AF; Hou J; Chen L; Wu J; Guo Y; Synold TW; Ngo VN; Puverel S; Mei M; Popplewell L; Yi S; Song JY; Tao S; Wu X; Chan WC; Forman SJ; Kwak LW; Rosen ST; Newman EM
    Clin Cancer Res; 2020 Mar; 26(5):1034-1044. PubMed ID: 31811017
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Scarisbrick JJ
    Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells.
    Weniger MA; Tiacci E; Schneider S; Arnolds J; Rüschenbaum S; Duppach J; Seifert M; Döring C; Hansmann ML; Küppers R
    J Clin Invest; 2018 Jul; 128(7):2996-3007. PubMed ID: 29889102
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease.
    Gruss HJ; Hirschstein D; Wright B; Ulrich D; Caligiuri MA; Barcos M; Strockbine L; Armitage RJ; Dower SK
    Blood; 1994 Oct; 84(7):2305-14. PubMed ID: 7522624
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Isolation of viable Hodgkin and Reed-Sternberg cells from Hodgkin disease tissues.
    Irsch J; Nitsch S; Hansmann ML; Rajewsky K; Tesch H; Diehl V; Jox A; Küppers R; Radbruch A
    Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10117-22. PubMed ID: 9707610
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cocktails of ricin A-chain immunotoxins against different antigens on Hodgkin and Sternberg-Reed cells have superior anti-tumor effects against H-RS cells in vitro and solid Hodgkin tumors in mice.
    Engert A; Gottstein C; Bohlen H; Winkler U; Schön G; Manske O; Schnell R; Diehl V; Thorpe P
    Int J Cancer; 1995 Oct; 63(2):304-9. PubMed ID: 7591221
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
    Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
    Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Age-dependent changes of serum soluble CD30 concentration in children.
    Chrul S; Polakowska E
    Pediatr Transplant; 2011 Aug; 15(5):515-8. PubMed ID: 21672104
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Frequent expression of CD30 in extranodal NK/T-cell lymphoma: Potential therapeutic target for anti-CD30 antibody-based therapy.
    Kawamoto K; Miyoshi H; Suzuki T; Sasaki Y; Yamada K; Yanagida E; Muto R; Kiryu M; Sone H; Seto M; Ohshima K; Takizawa J
    Hematol Oncol; 2018 Feb; 36(1):166-173. PubMed ID: 29052238
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CD30 Cross-Reactivity and Expression in Feline Normal Tissues and Lymphomas.
    Carminato A; Tecilla M; Roccabianca P; Zanardello C; Melchiotti E; Capello K; Vascellari M
    Vet Pathol; 2020 Jan; 57(1):49-55. PubMed ID: 31640480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Release of soluble CD30 after allogeneic stimulation is mediated by memory T cells and regulated by IFN-γ and IL-2.
    Velásquez SY; García LF; Opelz G; Alvarez CM; Süsal C
    Transplantation; 2013 Jul; 96(2):154-61. PubMed ID: 23857000
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma.
    Makita S; Maruyama D; Tobinai K
    Onco Targets Ther; 2020; 13():5993-6009. PubMed ID: 32606807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 3D image analysis reveals differences of CD30 positive cells and network formation in reactive and malignant human lymphoid tissue (classical Hodgkin Lymphoma).
    Liebers J; Wurzel P; Reisinger KB; Hansmann ML
    PLoS One; 2019; 14(10):e0224156. PubMed ID: 31648255
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Challenges of driving CD30-directed CAR-T cells to the clinic.
    Grover NS; Savoldo B
    BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.